In the monarchE trial, high-risk early BC was defined as the presence of either four or more positive axillary lymph nodes or one to three positive axillary lymph nodes with at least one of the following features: grade 3 disease, a tumor size of 5 cm or larger, and a Ki-67 proliferative index of at least 20% [5]. The gene discussed is MKI67; the disease is neoplasm.